BIVI241018C1000
- 0.05
- 0.000.00%
BioVie Newsroom
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie Receives Notice Of Allowance For U.S. Patent Application Covering Novel Liquid Formulation Of Terlipressin
Express News | BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin
BioVie | 10-K: FY2024 Annual Report
12 Health Care Stocks Moving In Thursday's After-Market Session
BioVie Bolsters Capital With Public Offering and Warrant Adjustment
Top Midday Decliners
Why BioVie (BIVI) Stock Is Down Over 50% Today
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Sector Update: Health Care
Seelos SEEL US Army Trial; BioVie BIVI Offering
Reported Earlier, BioVie Raised $3M VIa Secondary Stock Offering Of 1.96M Shares At $1.53/Share
BioVie Plummets 50%, Prices $3M Gross Proceeds
BioVie Intends to Use Proceeds Primarily for Working Capital >BIVI
BioVie: Combined Offering Price Set at $1.53 Per Share >BIVI
Press Release: BioVie Inc. Announces Proposed Public Offering
Express News | BioVie Inc. Announces Proposed Public Offering
BioVie Announces Approval From U.S. Army Medical Research and Development Command, Office of Human Research Oversight For Its Plan To Evaluate Bezisterim In Long Covid, Co. Receives $13.1M In Funding
Top Premarket Gainers
Express News | BioVie Inc - on Track to Receive Additional $12.6 Mln in Grant Funding From U.S. Department of Defense ("Dod") and Initiate Its Phase 2 Trial